sibutramine

(redirected from Sibutramine hydrochloride)
Also found in: Dictionary.
Related to Sibutramine hydrochloride: Reductil

sibutramine

 [si-bu´trah-mēn″]
an appetite suppressant used as the hydrochloride salt in treatment of obesity; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

sibutramine

(sə-byo͞o′trə-mĭn, -mēn′)
n.
A drug formerly used in the management of obesity, withdrawn from the US market in 2010 because of its association with an increased risk of heart attacks and strokes.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

sibutramine

A central, appetite-suppressing agent that blocks reuptake of serotonin, norepinephrine and, to a lesser extent, dopamine; it provides a sensation of fullness from lesser amounts of food, and increases metabolism. Sibutramine was approved for use as a dietary adjunct in the mid-1990s and was heavily marketed until 2010, when it was withdrawn from the market due to the increased risk of cardiovascular events and strokes associated with its use. Sibutramine is a Schedule-IV Controlled Substance.

 
Indications
Obese patients with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 in addition to other factors (e.g., hypertension, diabetes, dyslipidemia).

Adverse effects
Headache, dry mouth, anorexia, constipation.

Contraindications
Concurrent MAOIs, other central appetite suppressants, anorexia nervosa.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

sibutramine

Meridia® Obesity A central, appetite-suppressing agent that blocks reuptake of serotonin and norepinephrine, and, to a lesser extent dopamine; it provides a sensation of fullness from less food, and ↑ metabolism Indications Obese Pts with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 with other factors–eg, HTN, DM, dyslipidemia Cons Sibutramine is a Schedule IV Controlled Substance Adverse effects Headache, dry mouth, anorexia, constipation Contraindications Concurrent MAOIs, other central appetite suppressants, anorexia nervosa. See Obesity.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

si·bu·tra·mine

(si-byū'tră-mēn)
A serotonin and noradrenaline reuptake inhibitor used to reduce appetite to encourage weight loss.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

sibutramine

An antiobesity drug that acts on the nervous system in a manner similar to that of Prozac so that the patient is able to feel satisfied with smaller amounts of food. The drug is not recommended for people under 18 and is used for a maximum period of one year. It is prescribed mainly for those with a body mass index (BMI) of 30 or over. Brand name Reductil.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

Sibutramine

An appetite-suppressing drug that may increase the activity of norepinephrine and serotonin in the brain.
Mentioned in: Weight Loss Drugs
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.

si·bu·tra·mine

(si-byū'tră-mēn)
A serotonin and noradrenaline reuptake inhibitor used to reduce appetite to encourage weight loss.
Medical Dictionary for the Dental Professions © Farlex 2012
References in periodicals archive ?
Among these products are the two most widely prescribed anti obesity drugs orlistat (Xenical-Roche) and sibutramine hydrochloride (Meridia-Abbott Laboratories).
Sold by Abbott Laboratories as Meridia, sibutramine hydrochloride gained U.S.